Barry Kappel, Sapience Therapeutics CEO

Pep­tide biotech gets re­newed sup­port from Bris­tol My­ers, oth­ers to bankroll mul­ti­ple on­col­o­gy clin­i­cal pro­grams

The first batch of fi­nanc­ing last­ed about five years, but this time around, Sapi­ence Ther­a­peu­tics thinks its new fund­ing round will have run­way for less …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.